Mirzotamab
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax , a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC)[2][3].
Product Specifications
CAS Number
2229859-11-2
UNSPSC
12352203
Target
ADC Antibody; CD276/B7-H3
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mirzotamab.html
Purity
99.45
Solubility
10 mM in DMSO
Smiles
[Mirzotamab]
Molecular Weight
(144.86 kDa)
References & Citations
[1]Tolcher A W, et al. A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results. 2021. |[2]Cai Jiaqiang, et al. Antibody-drug conjugate containing BCL-2 family proteolysis agent, preparation method therefor, and use thereof. WO2024153185. 2024.07.25.|[3]Nathanson, David A., et al. Combination therapy for treating glioblastoma. WO2022231996. 2022.11.03.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K3453604 1.0 µg DNA
Fut11 sgRNA CRISPR Lentivector (Mouse) (Target 3)
Sign In for Pricing
View Details